Trial Profile
A European Multicentre Double-blind Placebo-controlled Phase III Trial of Nilvadipine in Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jan 2022
Price :
$35
*
At a glance
- Drugs Nilvadipine (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NILVAD; NILVAD2012
- 11 Jan 2022 This trial has been completed in Garmany, according to European Clinical Trials Database record. (16 Dec 2016)
- 14 Sep 2020 Results assessing prevalence of sedative medication use in community-dwelling older adults with mild-moderate AD and the longitudinal association between sedative medication use and adverse events, published in the Drugs and Aging.
- 01 Nov 2019 Results of post-hoc analysis assessing whether blood pressure variability and functional decline in Alzheimer disease published in the Hypertension